Remove Medical Remove Radiopharmaceuticals Remove Radiosensitivity
article thumbnail

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

Imaging Technology

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1, Gauden , D.Phil., Chief Executive Officer of Blue Earth Therapeutics.

article thumbnail

TeleDaaS Launches as Premier Provider of Dosimetry as a Service for Clinical Research Organizations

Imaging Technology

"We are launching TeleDaaS today to arm those researching and developing breakthrough cancer treatments with the technology and services needed to usher in the next generation of precision cancer therapies,” said TeleDaaS Chief Medical Officer Dr. Mark Crockett, M.D. TeleDaaS licenses a cloud-based technology platform from Mirada Medical.

Clinic 78